newsfilter
← Latest News
GlobeNewswire·

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Phase 3 Pivotal Cardigan II study exceeds 50% enrollment- - -Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021 BOULDER, Colo., April 27, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or